Retirement Systems of Alabama boosted its position in Syneos Health Inc (NASDAQ:SYNH) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 79,622 shares of the company’s stock after purchasing an additional 341 shares during the quarter. Retirement Systems of Alabama’s holdings in Syneos Health were worth $4,068,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in SYNH. Norges Bank acquired a new stake in Syneos Health in the 4th quarter valued at approximately $24,850,000. Rubric Capital Management LP acquired a new stake in Syneos Health in the 1st quarter valued at approximately $23,121,000. Rothschild & Co. Asset Management US Inc. raised its position in Syneos Health by 196.3% in the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 583,089 shares of the company’s stock valued at $30,181,000 after buying an additional 386,294 shares during the last quarter. Boston Partners raised its position in Syneos Health by 24.8% in the 1st quarter. Boston Partners now owns 1,036,119 shares of the company’s stock valued at $53,629,000 after buying an additional 205,892 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its position in Syneos Health by 26.8% in the 1st quarter. Pictet Asset Management Ltd. now owns 819,900 shares of the company’s stock valued at $42,438,000 after buying an additional 173,498 shares during the last quarter.
Shares of NASDAQ:SYNH traded down $0.10 during trading on Wednesday, hitting $52.15. 145,735 shares of the company were exchanged, compared to its average volume of 290,470. The stock has a market capitalization of $5.10 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 1.76 and a beta of 1.53. Syneos Health Inc has a fifty-two week low of $36.26 and a fifty-two week high of $56.34. The firm has a fifty day simple moving average of $49.14. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 1.07.
A number of equities research analysts recently issued reports on the company. ValuEngine raised Yandex from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Wolfe Research assumed coverage on Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Zacks Investment Research lowered Hammerson from a “hold” rating to a “sell” rating in a research report on Friday, May 24th. Finally, Barclays set a $24.00 price target on Tenet Healthcare and gave the stock a “hold” rating in a research report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $53.33.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Article: How the Consumer Price Index (CPI) is calculated?
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.